Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-07-06 DOI:10.1016/j.clgc.2024.102155
Mikaela Dell'Oro , Daniel T. Huff , Ojaswita Lokre , Jake Kendrick , Rajkumar Munian Govindan , Jeremy S.L. Ong , Martin A. Ebert , Timothy G. Perk , Roslyn J. Francis
{"title":"Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer","authors":"Mikaela Dell'Oro ,&nbsp;Daniel T. Huff ,&nbsp;Ojaswita Lokre ,&nbsp;Jake Kendrick ,&nbsp;Rajkumar Munian Govindan ,&nbsp;Jeremy S.L. Ong ,&nbsp;Martin A. Ebert ,&nbsp;Timothy G. Perk ,&nbsp;Roslyn J. Francis","doi":"10.1016/j.clgc.2024.102155","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Treatment of men with metastatic prostate cancer can be difficult due to the heterogeneity of response of lesions. [<sup>68</sup>Ga]Ga-PSMA-11 (PSMA) PET/CT assists with monitoring and directing clinical intervention; however, the impact of response heterogeneity has yet to be related to outcome measures. The aim of this study was to assess the impact of quantitative imaging information on the value of PSMA PET/CT to assess patient outcomes in response evaluation.</p></div><div><h3>Patients and Methods</h3><p>Baseline and follow-up (6 months) PSMA PET/CT of 162 men with oligometastatic PC treated with standard clinical care were acquired between 2015 and 2016 for analysis. An augmentative software medical device was used to track lesions between scans and quantify lesion change to categorize them as either new, increasing, stable, decreasing, or disappeared. Quantitative imaging features describing the size, intensity, extent, change, and heterogeneity of change (based on percent change in SUV<sub>total</sub>) among lesions were extracted and evaluated for association with overall survival (OS) using Cox regression models<em>.</em> Model performance was evaluated using the c-index.</p></div><div><h3>Results</h3><p>Forty-one (25%) of subjects demonstrated heterogeneous response at follow-up, defined as having at least 1 new or increasing lesion and at least 1 decreasing or disappeared lesion. Subjects with heterogeneous response demonstrated significantly shorter OS than subjects without (median OS = 76.6 months vs. median OS not reached, <em>P</em> &lt; .05, c-index = 0.61). In univariate analyses, SUV<sub>total</sub> at follow-up was most strongly associated with OS (HR = 1.29 [1.19, 1.40], <em>P</em> &lt; .001, c-index = 0.73). Multivariable models applied using heterogeneity of change features demonstrated higher performance (c-index = 0.79) than models without (c-index = 0.71-0.76, <em>P</em> &lt; .05).</p></div><div><h3>Conclusion</h3><p>Augmentative software tools enhance the evaluation change on serial PSMA PET scans and can facilitate lesional evaluation between timepoints. This study demonstrates that a heterogeneous response at a lesional level may impact adversely on patient outcomes and supports further investigation to evaluate the role of imaging to guide individualized patient management to improve clinical outcomes.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001265/pdfft?md5=3b87b98001d137960ac1997a55df260e&pid=1-s2.0-S1558767324001265-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Treatment of men with metastatic prostate cancer can be difficult due to the heterogeneity of response of lesions. [68Ga]Ga-PSMA-11 (PSMA) PET/CT assists with monitoring and directing clinical intervention; however, the impact of response heterogeneity has yet to be related to outcome measures. The aim of this study was to assess the impact of quantitative imaging information on the value of PSMA PET/CT to assess patient outcomes in response evaluation.

Patients and Methods

Baseline and follow-up (6 months) PSMA PET/CT of 162 men with oligometastatic PC treated with standard clinical care were acquired between 2015 and 2016 for analysis. An augmentative software medical device was used to track lesions between scans and quantify lesion change to categorize them as either new, increasing, stable, decreasing, or disappeared. Quantitative imaging features describing the size, intensity, extent, change, and heterogeneity of change (based on percent change in SUVtotal) among lesions were extracted and evaluated for association with overall survival (OS) using Cox regression models. Model performance was evaluated using the c-index.

Results

Forty-one (25%) of subjects demonstrated heterogeneous response at follow-up, defined as having at least 1 new or increasing lesion and at least 1 decreasing or disappeared lesion. Subjects with heterogeneous response demonstrated significantly shorter OS than subjects without (median OS = 76.6 months vs. median OS not reached, P < .05, c-index = 0.61). In univariate analyses, SUVtotal at follow-up was most strongly associated with OS (HR = 1.29 [1.19, 1.40], P < .001, c-index = 0.73). Multivariable models applied using heterogeneity of change features demonstrated higher performance (c-index = 0.79) than models without (c-index = 0.71-0.76, P < .05).

Conclusion

Augmentative software tools enhance the evaluation change on serial PSMA PET scans and can facilitate lesional evaluation between timepoints. This study demonstrates that a heterogeneous response at a lesional level may impact adversely on patient outcomes and supports further investigation to evaluate the role of imaging to guide individualized patient management to improve clinical outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估前列腺癌生化复发患者对[68Ga]Ga-PSMA-11 PET/CT病灶反应的异质性
导言:由于病变反应的异质性,治疗男性转移性前列腺癌非常困难。[68Ga]Ga-PSMA-11(PSMA)PET/CT有助于监测和指导临床干预;然而,反应异质性的影响尚未与结果测量相关联。本研究旨在评估定量成像信息对PSMA PET/CT在反应评估中评估患者预后价值的影响。患者和方法在2015年至2016年期间获得了162名接受标准临床治疗的少转移性PC男性患者的基线和随访(6个月)PSMA PET/CT进行分析。使用增强型软件医疗设备跟踪扫描之间的病变,并量化病变变化,将其分为新发、增加、稳定、减少或消失。提取描述病变大小、强度、范围、变化和变化异质性(基于 SUVtotal 的变化百分比)的定量成像特征,并使用 Cox 回归模型评估其与总生存期(OS)的关系。结果41名受试者(25%)在随访时表现出异质性反应,异质性反应的定义是至少有1个新发病灶或病灶增大,至少有1个病灶缩小或消失。有异质性反应的受试者的 OS 明显短于无异质性反应的受试者(中位 OS = 76.6 个月 vs. 未达到中位 OS,P < .05,c-index = 0.61)。在单变量分析中,随访时的 SUVtotal 与 OS 的关系最为密切(HR = 1.29 [1.19, 1.40],P < .001,c-index = 0.73)。使用异质性变化特征的多变量模型比不使用异质性变化特征的模型表现出更高的性能(c-index = 0.79)(c-index = 0.71-0.76, P < .05)。这项研究表明,病灶层面的异质性反应可能会对患者的预后产生不利影响,因此支持进一步研究评估成像在指导患者个体化管理以改善临床预后方面的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1